Arctigenin (AG) is a dibenzylbutyrolactone lignan found particularly in the fruit/seeds of Arctium lappa L. (burdock). It is the aglycone of arctiin. Mammalian research reports anti-inflammatory, neuroprotective, metabolic, anticancer, vascular, antiviral, and immunomodulatory actions. However, an important distinction is necessary: most therapeutic evidence is preclinical. Human interventional evidence is limited, with the most notable study involving an arctigenin-rich Arctium lappa fruit extract (GBS-01) in advanced pancreatic cancer.
1. Human Study: Advanced Pancreatic Cancer
One of the most important findings for arctigenin is that it has actually reached human clinical investigation.
GBS-01, an Arctium lappa fruit extract standardized to contain arctigenin, was evaluated in patients with advanced pancreatic cancer refractory to gemcitabine. This was an open-label phase I dose-escalation study, primarily intended to establish safety and an appropriate dose rather than prove efficacy.
Fifteen patients received GBS-01. Pharmacokinetic analysis showed systemic exposure to arctigenin after oral administration and rapid glucuronidation. The investigators reported one partial response and several cases of stable disease, but the study was far too small and uncontrolled to establish anticancer efficacy.
Full Reference:
Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, et al. Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. Cancer Science. 2016;107(12):1818-1824. doi:10.1111/cas.13086.
2. Alzheimer’s Disease: Improved Memory In Mice
Arctigenin has unusually interesting preclinical data in Alzheimer’s disease.
In Alzheimer’s-model mice, arctigenin improved memory impairment and appeared to attack amyloid pathology through two complementary mechanisms:
decreasing Aβ production + increasing Aβ clearance.
The investigators reported inhibition of β-secretase activity and enhancement of autophagic clearance of Aβ. Behavioral testing showed improvement in memory deficits.
This is one of the stronger mammalian studies of arctigenin because it combined biochemical, cellular, pathological, and behavioral endpoints. It nevertheless remains a mouse-model result, not evidence that arctigenin treats human Alzheimer’s disease.
Full Reference:
Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L, Li C, Hu L, Jiang H, Shen X. Arctigenin effectively ameliorates memory impairment in Alzheimer’s disease model mice targeting both β-amyloid production and clearance. Journal of Neuroscience. 2013;33(32):13138-13149. doi:10.1523/JNEUROSCI.4790-12.2013. PMID:23926267.
3. Amyloid-β–Induced Cognitive Impairment And Tau Pathology
Another mouse investigation found that arctigenin improved learning and memory abnormalities associated with Aβ exposure.
The proposed mechanism involved suppression of hyperphosphorylated tau, with effects on the PI3K/Akt/GSK-3β pathway.
This adds an interesting dimension to the Alzheimer’s research because arctigenin may influence both major pathological pathways:
Aβ pathology + tau phosphorylation.
Full Reference:
Qi Y, Dou DQ, Jiang H, Zhang BB, Qin WY, Kang K, Zhang N, Jia D. Arctigenin attenuates learning and memory deficits through PI3K/Akt/GSK-3β pathway reducing tau hyperphosphorylation in Aβ-induced AD mice. Planta Medica. 2017;83(1-02):51-56. PMID:27224270.
4. Neuroinflammation And Microglial Activation
Arctigenin has demonstrated neuroprotective effects in mammalian inflammatory models.
Experimental work indicates reductions in inflammatory mediators and suppression of pathways involving activated microglia. NF-κB and MAPK-related signaling have been implicated.
This is potentially relevant because chronic microglial activation contributes to secondary neuronal injury in numerous neurological diseases. However, translation from experimental neuroinflammation to human neurodegenerative disease remains unproven.
Full Reference:
Zhang N, et al. Neuroprotective effect of arctigenin against neuroinflammation and oxidative stress induced by rotenone. Experimental mammalian and cellular investigation. The study reports suppression of inflammatory/oxidative responses and protection of neuronal function.
5. Multiple Sclerosis Model: Experimental Autoimmune Encephalomyelitis
Arctigenin has also been investigated in experimental autoimmune encephalomyelitis (EAE), the major animal model used to investigate multiple sclerosis.
Treatment ameliorated EAE manifestations and reduced neuroinflammatory pathology. The investigators implicated modulation of the AMPK/PPAR-γ pathway and immune responses.
This provides evidence for immunomodulatory and neuroprotective effects in an intact mammalian autoimmune model, but does not establish efficacy in human MS.
Full Reference:
Wei L, et al. Arctigenin exerts neuroprotective effect by ameliorating neuroinflammation in experimental autoimmune encephalomyelitis through the AMPK/PPAR-γ pathway. Frontiers in Immunology. 2021;12:691590. doi:10.3389/fimmu.2021.691590.
6. Subarachnoid Hemorrhage And Cerebral Vasospasm
Arctigenin has been tested in a rodent model of subarachnoid hemorrhage (SAH).
Administration increased endothelial nitric oxide synthase (eNOS) signaling and decreased endothelin-1-associated cerebral vasospasm.
The study suggests a potentially useful vascular/endothelial action:
↑ eNOS/NO signaling → ↓ vasoconstriction/vasospasm.
This remains preclinical.
Full Reference:
Chang CZ, Wu SC, Kwan AL, Lin CL. Arctigenin, a potent ingredient of Arctium lappa L., induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat model. BioMed Research International. 2015;2015:490209.
7. Anti-Inflammatory Effects
Anti-inflammatory activity is among the most consistently reported biological properties of arctigenin.
Mammalian and cellular studies have reported modulation of:
- NF-κB
- MAPKs
- nitric oxide/iNOS
- TNF-α
- IL-1β
- IL-6
- inflammasome-associated pathways
- macrophage activation.
The significance is broader than any single disease model: inflammatory signaling appears to be one of arctigenin’s recurring pharmacological targets.
Full Reference:
Gao Q, Yang M, Zuo Z. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L. Acta Pharmacologica Sinica. 2018;39(5):787-801. doi:10.1038/aps.2018.32. PMID:29698388.
8. Acute Hepatitis/Liver Inflammation In Mice
Arctigenin has demonstrated hepatoprotective activity in experimental acute hepatitis.
Animal research indicates that arctigenin can reduce immune-mediated hepatic injury by modifying inflammatory-cell responses and inflammatory signaling.
This provides an important distinction: some of arctigenin’s reported liver benefits may arise from immunomodulation rather than simply direct antioxidant activity.
Full Supporting Review:
Pu Z, et al. Systematic understanding of the mechanism and effects of arctigenin against inflammatory diseases. Frontiers in Pharmacology. 2019. The review discusses the primary mouse acute-hepatitis experiments demonstrating protection against inflammatory liver injury.
9. Metabolic Dysfunction-Associated Steatohepatitis And Liver Fibrosis
A newer mouse study investigated arctigenin in diet-induced metabolic dysfunction-associated steatohepatitis (MASH).
Arctigenin treatment reduced several pathological features, including:
hepatic inflammation + oxidative stress + fibrosis.
This is potentially important because fibrosis is a more disease-relevant endpoint than simply lowering an isolated inflammatory biomarker. Nevertheless, it remains an animal study and does not establish treatment efficacy for human MASH.
Full Reference:
Xue R, et al. Arctigenin prevents metabolic dysfunction-associated steatohepatitis by attenuating liver inflammation, oxidative stress and fibrosis. Journal of Clinical and Translational Hepatology. 2025.
10. Hepatocellular Carcinoma: Mouse Tumor Evidence
Arctigenin inhibited hepatocellular carcinoma cell proliferation, migration and invasion in experimental systems.
Importantly, the investigation extended beyond cell culture and showed inhibition of tumor growth in a mouse xenograft model. Gankyrin was identified as an important molecular target.
This represents genuine in-vivo anticancer evidence, but xenograft tumor suppression is still several steps removed from demonstrating efficacy in human HCC.
Full Reference:
Sun Y, Tan YJ, Lu ZZ, Li BB, Sun CH, Li T, et al. Arctigenin inhibits liver cancer tumorigenesis by inhibiting gankyrin expression via C/EBPα and PPARα. Frontiers in Pharmacology. 2018;9:268. doi:10.3389/fphar.2018.00268.
11. Antiviral/Anti-Influenza Effects
Arctigenin and related Arctium lignans have been investigated for antiviral effects, particularly against influenza.
Reported mechanisms include direct antiviral effects as well as suppression of excessive inflammatory responses associated with infection. Reviews of the mammalian literature describe survival/protective effects in experimental influenza models.
This is preclinical evidence and should not be interpreted as demonstrating that arctigenin prevents or treats influenza in humans.
Full Reference/Review:
Gao Q, Yang M, Zuo Z. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L. Acta Pharmacologica Sinica. 2018;39(5):787-801. doi:10.1038/aps.2018.32.
12. Antibacterial And Anti-Virulence Activity Against Pseudomonas aeruginosa
A particularly interesting recent study investigated arctigenin against P. aeruginosa.
Arctigenin demonstrated antibacterial activity associated with bacterial membrane disruption and also affected quorum sensing and virulence-associated properties. Importantly, the investigation included both in-vitro and in-vivo components.
This could be relevant to biofilm research because quorum sensing contributes to P. aeruginosa virulence and biofilm physiology. It should not yet be characterized as clinical evidence for treatment of human Pseudomonas infection.
Full Reference:
Koshak AE, et al. Arctigenin from burdock root exhibits potent antibacterial and anti-virulence activities against Pseudomonas aeruginosa. 2024. PMID:39049476.
13. Pharmacokinetics: Arctigenin Reaches Multiple Mammalian Tissues
For any proposed therapeutic compound, a central question is whether it can actually reach tissues after administration.
Rat pharmacokinetic research demonstrates that arctigenin undergoes extensive metabolism but distributes to multiple tissues. Pharmacokinetic modeling after oral and intravenous administration showed substantial first-pass metabolism and conjugation.
Full Reference:
Gao Q, Zhang Y, Wo S, Zuo Z. Elucidation of arctigenin pharmacokinetics after intravenous and oral administrations in rats: integration of in vitro and in vivo findings via semi-mechanistic pharmacokinetic modeling. AAPS Journal. 2014;16(6):1321-1333.
14. Arctiin Can Serve As A Precursor Of Arctigenin In Mammals
Arctiin is the glycoside precursor of arctigenin. After oral administration, metabolism by intestinal microorganisms and mammalian processes can generate arctigenin.
Rat pharmacokinetic studies found appreciable systemic arctigenin following oral administration of arctiin. This is important when interpreting experiments using Arctium lappa extracts rather than purified arctigenin.
Full Reference:
He F, Dou DQ, Sun Y, Zhu L, Xiao HB, Kang TG. Plasma pharmacokinetics and tissue distribution of arctiin and its main metabolite arctigenin after oral administration of arctiin in rats. Planta Medica. 2012;78(8):800-806. PMID:22499560.
15. Human Pharmacokinetics
The pancreatic-cancer phase I study provides something relatively uncommon for a plant lignan: human pharmacokinetic data.
After oral administration of the arctigenin-containing preparation, arctigenin became systemically available but underwent rapid glucuronide conjugation.
This may be one of the major barriers to translating impressive cell-culture concentrations into human therapy because free arctigenin exposure may differ dramatically from nominal oral doses.
Full Reference:
Ikeda M, Sato A, Mochizuki N, et al. Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. Cancer Science. 2016;107(12):1818-1824. doi:10.1111/cas.13086.
16. Safety: High-Dose Animal Toxicity Deserves Attention
Arctigenin should not automatically be considered harmless because it is plant-derived.
A 28-day oral toxicity study in rats identified treatment-related abnormalities involving several organs at sufficiently high exposures, including changes affecting the liver, kidney, heart, lung and reproductive tissues.
This is particularly important when extrapolating from experimental pharmacology to chronic supplementation in humans.
Full Reference:
Tan Y, et al. 28-Day oral chronic toxicity study of arctigenin in rats. 2018. The investigators performed repeated-dose toxicity assessment with clinical chemistry, hematological and histopathological evaluation and identified dose-associated organ toxicity.
Overall Evidence Assessment
The mammalian literature makes arctigenin a biologically interesting investigational compound, particularly for inflammation and neuroprotection. The most compelling areas currently appear to be neuroinflammation/Alzheimer-model research, immune-inflammatory modulation, metabolic/liver disease, vascular protection, infection/virulence research, and experimental oncology.
But the evidence pyramid is very uneven:
- Cell studies → numerous
- Mouse/rat studies → substantial
- Human pharmacokinetic data → limited
- Human therapeutic trials → very limited
- Large randomized controlled trials demonstrating health benefits → essentially lacking
Therefore, findings such as improved memory, reduced inflammation, decreased fibrosis, or tumor inhibition should be described as animal/preclinical findings, not established human health benefits.
The human GBS-01 pancreatic-cancer trial is especially valuable because it establishes that an orally administered arctigenin-rich preparation can produce measurable human exposure and provides preliminary safety information—but it does not establish clinical efficacy of arctigenin for cancer or other diseases.